Sort
48,018 grants matching “immunotherapy”
Molecular Genetic Analysis of Mycobacterium Tuberculosis
$803,583William Robert Jacobs · Albert Einstein College Of Medicine · R37 · FY2023 · AI
Comparative Modeling for the Prevention and Control of Uterine Cancer
$803,402Jason Wright · Columbia University Health Sciences · U01 · FY2024 · CA
Recombinant Interleukin-12 for Cutaneous T-Cell Lymphoma
$803,305University Of Pennsylvania · R01 · FY2002 · CA
Immunotherapy of low grade lymphoid malignancies
$803,050Adrian U Wiestner · National Heart, Lung, And Blood Institute · ZIA · FY2020 · HL
Colaboracion Evita: HPV-Related Cancer Prevention Partnership Center
$803,006Margaret M Madeleine · Fred Hutchinson Cancer Research Center · U54 · FY2021 · CA
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
$802,815Charles Bix Shoemaker · Tufts University Boston · R01 · FY2024 · AI
Miami Center for AIDS Research
$802,550Savita Pahwa · University Of Miami School Of Medicine · P30 · FY2024 · AI
Project II: Immune regulatory circuits in primary colon cancer and lymph node and liver metastases
$802,523Alexander Y. Rudensky · Sloan-Kettering Inst Can Research · U54 · FY2024 · CA
Clinical Fellowship Training Program
$802,495Peter Pinto · Division Of Basic Sciences - Nci · ZIE · FY2019 · CA
Targeting Neuroblastoma with armed T cells
$802,464Lawrence G Lum · Wayne State University · R01 · FY2014 · CA
New therapeutics for Shiga toxin-E. coli disease.
$802,386Tom G Obrig · University Of Virginia · U01 · FY2007 · AI
Cellular, molecular and quantitative imaging analysis of screening-detected lung adenocarcinoma
$802,247Pierre P Massion · Vanderbilt University Medical Center · U01 · FY2016 · CA
Immunotherapy to prevent drug-resistant tuberculosis
$802,216Rhea N Coler · Access To Advanced Health Institute · R01 · FY2019 · AI
Chemoattractant-based immunotherapeutics to modulate immune and cancer cells
$802,045Arya Arya · Aging · Z01 · FY2007 · AG
Reprograming the tumor microenvironment to overcome multiple primary and acquired immune resistance mechanisms in ovarian cancer
$802,002Kunle O Odunsi · Roswell Park Cancer Institute Corp · U01 · FY2019 · CA
A Cytochrome P450 Therapeutic Space for Tauopathies
$801,925Arvin Dar · Icahn School Of Medicine At Mount Sinai · R56 · FY2021 · AG
Leadership, Planning, and Evaluation
$801,888Ramesh A Shivdasani · Dana-Farber Cancer Inst · P30 · FY2024 · CA
Epithelium-derived alarmins role in breast cancer immunoprevention
$801,869Shadmehr Demehri · Massachusetts General Hospital · U01 · FY2022 · CA
Epithelium-derived alarmins role in breast cancer immunoprevention
$801,869Shadmehr Demehri · Massachusetts General Hospital · U01 · FY2018 · CA
Epithelium-derived alarmins role in breast cancer immunoprevention
$801,869Shadmehr Demehri · Massachusetts General Hospital · U01 · FY2019 · CA
Epithelium-derived alarmins role in breast cancer immunoprevention
$801,869Shadmehr Demehri · Massachusetts General Hospital · U01 · FY2021 · CA
CellRaft Array for Screening and Isolation of Highly Effective Cytotoxic T Cells
$801,617Paul Michael Armistead · Cell Microsystems, Inc. · R42 · FY2018 · AI
Stratifying Patient Immune Endotypes in Sepsis (SPIES Study)
$801,507Lyle L Moldawer · University Of Florida · R01 · FY2020 · GM
PEDIATRICS AIDS CLINICAL TRIALS GROUP
$801,400Columbia University Health Sciences · U01 · FY2002 · AI
CellRaft Array for Screening and Isolation of Highly Effective Cytotoxic T Cells
$801,389Paul Michael Armistead · Cell Microsystems, Inc. · R42 · FY2017 · AI